| Song YB, Hahn JY, Gwon HC, et al.
Upstream High-Dose Tirofiban Does Not Reduce Myocardial Infarct Size in Patients Undergoing Primary Percutaneous Coronary Intervention: A Magnetic Resonance Imaging Pilot Study. [JOURNAL ARTICLE]
Clin Cardiol 2009 Jun 30; 32(6):321-326.
Abstract | Full Citation |
| Valgimigli M, Campo G, de Cesare N, et al.
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. [Journal Article, Research Support, Non-U.S. Gov't]
Circulation 2009 Jun 30; 119(25):3215-22.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |
| Gibbs NM
Point-of-care assessment of antiplatelet agents in the perioperative period: a review. [Journal Article]
Anaesth Intensive Care 2009 May; 37(3):354-69.
Abstract | Full Citation |
| Park SJ, Oh IY, Kim KH, et al.
Minimal withdrawal of dual antiplatelet agents under the guidance of a point-of-care platelet activity assay early after drug-eluting stent implantation for surgical removal of renal cell carcinoma. [JOURNAL ARTICLE]
Int J Cardiol 2009 May 26.
Abstract | Full Citation | Find Related Articles |
| Cohen M
Antiplatelet therapy in percutaneous coronary intervention: A critical review of the 2007 AHA/ACC/SCAI guidelines and beyond. [JOURNAL ARTICLE]
Catheter Cardiovasc Interv 2009 Feb 2.
Abstract | Full Citation |
| Akima S, Hawthorne WJ, Favaloro E, et al.
Tirofiban and Activated Protein C Synergistically Inhibit the Instant Blood Mediated Inflammatory Reaction (IBMIR) from Allogeneic Islet Cells Exposure to Human Blood. [JOURNAL ARTICLE]
Am J Transplant 2009 May 20.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |
| Sakellariou D, Pastromas S, Koulouris S, et al.
First report of tirofiban-induced anemia (found in combination with severe thrombocytopenia). [Journal Article]
Tex Heart Inst J 2009; 36(1):55-7.
Abstract | Full Citation | Find Related Articles |
| Lin YL, Chen LL, Luo YK, et al.
Benefit of standard versus low-dose tirofiban for percutaneous coronary intervention in very elderly patients with high-risk acute coronary syndrome. [Journal Article]
Acta Pharmacol Sin 2009 May; 30(5):553-8.
Abstract | Full Citation | Find Related Articles |
| Brener SJ
The benefits of platelet glycoprotein IIb/IIIa receptor inhibition during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: drug-specific or class effect? [Comment, Editorial]
J Am Coll Cardiol 2009 May 5; 53(18):1674-6.
Full Citation | Publisher Full Text | Find Related Articles |
| De Luca G, Ucci G, Cassetti E, et al.
Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis. [Comparative Study, Journal Article, Meta-Analysis]
J Am Coll Cardiol 2009 May 5; 53(18):1668-73.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |
  |
